Mastodon

Trekvion® (Tablets) Instructions for Use

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

ATC Code

A13A (General tonic preparations)

Active Substance

Oxyethylammonium methylphenoxy acetate (Grouping name)

Dosage Form

Bottle OTC Icon Trekvion® Tablets 200 mg

Dosage Form, Packaging, and Composition

Tablets

1 tab.
Oxyethylammonium methylphenoxy acetate 200 mg

10 pcs. – blister packs – cardboard packs (10 pcs.) – Over-the-Counter
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
14 pcs. – blister packs – cardboard packs (14 pcs.) – Over-the-Counter
14 pcs. – blister packs (2 pcs.) – cardboard packs (28 pcs.) – Over-the-Counter
14 pcs. – blister packs (3 pcs.) – cardboard packs (42 pcs.) – Over-the-Counter

Clinical-Pharmacological Group

Preparation with adaptogenic and restorative action

Pharmacotherapeutic Group

General tonic preparations

Pharmacological Action

An adaptogenic agent. It stimulates the production of alpha and gamma interferons and affects the immune status of the body by activating the cellular and humoral links of immunity. It stimulates the phagocytic activity of macrophages.

It strengthens the body’s immune system, increases endurance during physical and mental stress, reduces the effect of various toxins, and increases the body’s resistance to hypoxia, low and high temperatures, and other adverse environmental factors.

Pharmacokinetics

Oxyethylammonium methylphenoxy acetate has high bioavailability, is rapidly metabolized in the liver, and is excreted by the kidneys mainly in the form of glucuronides. It does not accumulate in the body with long-term use.

Indications

As part of complex therapy: for the prevention and treatment of acute respiratory viral infections; during periods of high intellectual and heavy physical exertion; to increase the body’s resistance to various stressful influences (hypoxia, overheating, hypothermia) and adverse environmental effects (sudden climate change, adaptation to changes in atmospheric pressure).

ICD codes

ICD-10 code Indication
J06.9 Acute upper respiratory infection, unspecified
T67 Effects of heat and light
T68 Hypothermia
T70 Effects of air pressure and water pressure
Z57 Occupational exposure to risk factors
Z73.3 Stress, not elsewhere classified (physical and mental strain)
ICD-11 code Indication
CA07.0 Acute upper respiratory tract infection of unspecified site
NF01.Z Exposure to heat, unspecified
NF02 Hypothermia
NF04.Z Exposure to atmospheric pressure and water pressure, unspecified
QD84.Z Exposure to occupational risk factors, unspecified
QE01 Stress, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take Trekvion® tablets orally with water.

For the prevention and treatment of acute respiratory viral infections, take one 200 mg tablet twice daily for a duration of 10 to 14 days.

To increase resistance during periods of high intellectual or physical stress, take one 200 mg tablet once or twice daily. The duration of use is up to 30 days.

To enhance the body’s adaptation to stressful environmental factors (such as sudden climate change, hypoxia, or temperature extremes), initiate a course of one 200 mg tablet twice daily for 7 to 10 days prior to the expected exposure.

Administer the tablets in the morning and afternoon to prevent potential sleep disturbances. Do not exceed the maximum daily dose of 400 mg.

For long-term use beyond 30 days, consult a physician for evaluation and potential regimen adjustment.

The drug is contraindicated for children under 12 years of age.

Adverse Reactions

Rarely allergic reactions – hypersensitivity reactions, anaphylactic shock, anaphylaxis, angioedema.

Contraindications

Hypersensitivity to the active substance; children under 12 years of age; pregnancy, breastfeeding period.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Use in Hepatic Impairment

The drug is approved for use in hepatic impairment.

Use in Renal Impairment

The drug is approved for use in renal impairment.

Pediatric Use

Contraindicated for use in children under 12 years of age (due to lack of data on efficacy and safety of use).

Geriatric Use

Approved for use in elderly patients.

Special Precautions

If, during the use of the product, pronounced symptoms of the disease persist or worsen in patients with ARVI, the product should be discontinued and a doctor should be consulted.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS